Abstract. Malignant transformation is caused by multi-step genetic mutations, and growth factors are believed to play important roles in developing and maintaining malignant phenotype. However, there is no direct evidence that a specific growth factor contributes to malignant transformation of phenotypically normal cells. In order to assess the function of Acrogranin (also known as granulin epithelial precursor; GEP) in ovarian carcinogenesis, ovarian surface epithelial (OSE) cells, which are supposed to be the origin of primary ovarian epithelial cancer, were transfected with combined genes of hTERT, SV40 LT, and Acrogranin. Introduction of hTERT and SV40 LT was sufficient for immortalizing OSE cells but not enough for tumor formation in nude mice. In contrast, transfection and overexpression of Acrogranin in immortalized OSE cells showed augmented clonogenicity in soft agar and obvious tumorigenicity in nude mice. This is the first study showing evidence that a specific growth factor plays a direct role in malignant transformation in ovarian cancer development.
Introduction
Malignant tumor develops as a result of stepwise accumulation of various genetic alterations such as mutation, amplification or silencing. Although a number of gene abnormalities have been detected so far, it is not necessarily clear if all the aberrancy is inevitable in cancer development. Some of the growth factors such as TGF-ß, M-CSF or LPA and their receptor-mediated signalings are known to play important roles in cancer cell biology. Nevertheless, their role and contribution to cancer development are not fully elucidated (1, 2) . Acrogranin, which is also designated as granulin epithelial precursor (GEP), PC cell-derived growth factor, progranulin or proepithelin, is an 88-kDa glycoprotein that was identified as a growth factor secreted from a murineteratoma cell, PC (3, 4) . Physiologically, Acrogranin plays a significant role in development and wound repair (5, 6) . It has also been reported that Acrogranin is overexpressed in various types of malignant tumors such as glioma, breast, prostate, liver and ovarian cancers (7) (8) (9) (10) (11) (12) . Experimentally, overexpression of Acrogranin in cancer cell lines results in enhanced proliferation, and inhibition of the gene expression impairs cell growth. However, there is no direct evidence that overexpression of Acrogranin contributes to malignant transformation.
Ovarian cancer is the most lethal of all the gynecological malignancies, being responsible for ~50% of all the deaths in female genital tract cancer. Since the majority (75-80%) of ovarian cancer patients presents at an advanced-stage, little is known about the early genetic events that are involved in the development of this disease, despite a number of genetic abnormalities were found in fully developed ovarian cancer. We have previously established a method to evaluate the influence of these genetic abnormalities on ovarian canrcinogenesis, in which OSE, a putative origin of ovarian cancer, was tranfected with several cancer-related genes and examined the tumorigenicity in nude mice. We found that transfection of hTERT, SV40 LT, and c-ERBB2 or mutant Ha-RAS were sufficient for the transformation of OSE (13) . In this study, by using the same method, we show the first direct evidence that Acrogranin contributes to malignant transformation of OSE.
Materials and methods
Immunohistochemical staining for Acrogranin. Samples (16 cases of carcinoma composed of 4 stage I, 10 stage III, and 1 stage IV cases, and 13 LMP cases were all stage I) were obtained in surgical procedure and used with written consent under approval of the Ethics Committee of Kyoto University Hospital. Tissues were fixed in 10% phosphate-buffered formalin, dehydrated in ethanol, embedded in paraffin and sectioned. Samples were deparaffinized in xylene and ethanol and then retrieved with Target retrieval solution high PH (Dako Cytomation, Tokyo) for 15 min at 95˚C. Then samples were blocked for endogenous peroxidase with 0.3% H 2 O 2 /methanol for 15 min, followed by sequential incubation with normal rabbit serum for 30 min at room temperature, primary antibody (a goat polyclonal anti-Acrogranin antibody from Santa Cruz Biotechnology) overnight at 4˚C, secondary antibody (biotinylated anti-goat IgG antibody) for 30 min at room temperature, and peroxidase-conjugated streptavidin for 30 min at room temperature. Slides were stained with DAB and then with hematoxylin as counter staining. Assessment was done by two independent pathologists, and scored as strong when >50% of the tumor cells were stained strongly; as weak when 10-50% of tumor cells were stained at least weakly, and as negative if <10% cells were stained.
Cell culture. IOSE cells were obtained and maintained as previously described (14) . Briefly, ovarian surface epithelial cells were obtained during operation with written consent, and transfected with SV40 large T antigen (LT) and the human telomerase reverse transcriptase (hTERT). These cells were cultured in a 1:1 mixture of medium 199 and MCDB 105 (Sigma, St. Louis, MO). The human ovarian cancer cell lines A2780, SK-OV-3, and OVCAR-3 were maintained as previously reported (15) .
Construction of retroviral vectors and gene transfection. The plasmid containing Acrogranin cDNA (pCMV-SPORT6-Acrogranin) was obtained from Invitrogen Corporation (Carlsbad, CA, USA: clone ID 3457813). A retroviral vector pLHCX (Clontech; Franklin Lakes, NJ, USA) was converted to the Gateway destination vector by using the Gateway vector converting system (Invitrogen). Then a retroviral vector containing an expression cassette for Acrogranin (designated as pLHCX-Acrogranin) was constructed using Gateway technology. The final construct was transfected by lipofection into the packaging cell line, Amphopack293 (Clontech), and the supernatant containing amphotropic viruses was collected. Viruses were used to infect IOSE cells with 5 μg/ml 1,5-dimethyl-1,5-diazaundecamethylene polymethobromide (Nakarai tesque; Kyoto, Japan), followed by selection with hygromycin B (400 μg/ml).
Reverse transcription PCR. Total RNA was extracted from cultured IOSE cells using Trizol reagent (Invitrogen). Reverse transcription PCR was performed with the One Step RT-PCR kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. PCR amplification of 25 cycles was performed as follows: denaturation at 94˚C for 1 min, annealing at 55˚C for 1 min, and extension at 72˚C for 2 min. For evaluation of Acrogranin mRNA expression, Actin was used as an internal control by multiplexing the Acrogranin and Actin-specific primers in each reaction. Primers used were: Acrogranin: forward 5'-TGG TTC ACA CCC GCT GCA-3', reverse 5'-GTT GGG CAT TGG GCA GCA-3'; Actin: forward 5'-CCG CAA AGA CCT GTA CGC CA-3', reverse 5'-TGG ACT TGG GAG AGG ACT GG-3'.
WST-1 assay. Cells of 1x10 3 per each well were seeded in a 96-well plate (Iwaki, Tokyo, Japan) and cultured in 100 μl of the same medium as mentioned above for 48 h at 37˚C in a 5% CO 2 . Cells were washed once and 100 μl of the fresh medium and 10 μl of Premix WST-1 (Takara Bio, Shiga, Japan) were added to each well and then cells were cultured for 2 h at 37˚C in 5% CO 2 . Absorbance was measured at 450 nm by EMax Precision microplate reader (Molecular Devices, CA, USA). The experiments were repeated 6 times.
Assay of anchorage independence. Colony formation of IOSE cells transfected with Acrogranin or empty vector in semisolid agar was assayed by suspending 4x10 4 cells in 800 μl of 0.33% agarose and placing on the top of 800 μl of solidified 0.5% agarose (13) . Three weeks later, colonies >50 μm in Tumorigenicity assays. Female BALB/C athymic nude mice aged 6-8 weeks were purchased from CLEA Japan (Tokyo, Japan). The animals received proper care according to the rules of the Kyoto University Committee on Animal Care. Animal experiments were performed in compliance with the United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Guidelines. Positive colonies formed in semisolid agar were seeded again in dishes and cultured for several days. Then these cells were collected and 2.5x10 7 cells were injected subcutaneously into nude mice. If subcutaneous mass was confirmed, the mice were sacrificed and the tumors were resected and examined microscopically. Cells were considered non-tumorigenic if the mouse failed to form a tumor within 4 months of injection.
Statistical analysis. For analysis of between-group differences, P-values were determined using the Mann-Whitney U test and Chi-square test. A P-value <0.05 was considered significant.
Results
Immunohistochemical staining for Acrogranin in ovarian cancer. Sixteen cases of epithelial ovarian cancer as well as 13 cases of epithelial tumors of low malignant potential were stained for Acrogranin. Staining of Acrogranin in ovarian cancer is significantly stronger than that of borderline tumors (P<0.05), although the number of samples is relatively small (Fig. 1 and Table I ).
Construction of Acrogranin transformed cell line. Acrogranin was tranefected into IOSE cells with retroviral vectors and transfectants were selected with hygromycin B. Expression of mRNA was confirmed by RT-PCR. Expression of Acrogranin mRNA is strong in transfected IOSE cells as well as in human ovarian cancer cell lines A2780, SK-OV-3, and OVCAR-3. On the other hand, IOSE transfected with empty vector showed no expression of mRNA (Fig. 2) .
Effect of Acrogranin transfection on the proliferation of IOSE.
WST-1 assay was performed to evaluate whether transfected Acrogranin has an effect on proliferation activity. IOSE cells transfected with Acrogranin revealed significantly accelerated growth compared with empty vector-transfected IOSE cells (P<0.05) (Fig. 3) . Anchorage-independent growth capacity was examined by soft agar clonogenicity assay. Anchorageindependent growth in IOSE cells was significantly enhanced by Acrogranin transfection as well (P<0.001) (Fig. 4) Tumorigenicity of Acrogranin-transfected IOSE. In all the mice (n=8) inoculated with IOSE cells transfected with Acrogranin, solid tumors were formed under the skin in 5 weeks (Fig. 5A) . On the other hand, empty vector transformed IOSE cells did not form tumors in any of the mice within 4 months (Table II) . Macroscopically tumors were present as very hard nodules. Histological study revealed a poorly differentiated-type of carcinoma (Fig. 5B ) in which vascularization was prominent in the stroma (Fig. 5C ). Immunohistostaining of Acrogranin was diffusely positive in the tumor cells (Fig. 5D ).
Discussion
It is generally accepted that malignant tumor develops as a result of accumulation of genetic alterations, and in accordance ONCOLOGY REPORTS 17: 329-333, 2007 Table I. Correlation between histological grading and Acrogranin expression in epithelial ovarian tumors. ------------------------------------------------- LMP, low malignant potential. Table II . Tumor formation in nude mice. with this, a number of gene abnormalities have been reported in various tumor types. However, it has been difficult to evaluate directly if such abnormalities are really responsible and inevitable in the course of cancer development. Hahn et al succeeded in transforming a human primary cell by the transfection of a defined combination of genes (16) . Other similar studies have been conducted showing that in vitro transformation study is a useful method to evaluate whether a specific genetic event was essential for the development of malignant tumors.
-------------------------------------------------
Epithelial ovarian cancer is believed to derive from ovarian surface epithelium (OSE), a single layered epithelium covering the ovarian surface. We previously cultured OSE and transfected several genes in an attempt to evaluate the effect on the transformation of OSE. Transfection of hTERT and SV40 LT resulted in immortalization of OSE (IOSE), preserving its original phenotype such as the inability to form tumors in nude mice. Further transfection of c-ERBB2 or mutant Ha-RAS was sufficient for full malignant transformation presenting as tumor formation in nude mice (13) . These data suggest that the method is a useful tool to assess the ability of specific genes to influence ovarian carcinogenesis. In this study, we focused on Acrogranin, a growth factor identified in highly tumorigenic PC murine-teratoma cells. Acrogranin is also highly expressed in cell lines and clinical specimens of ovarian cancer. According to Davidson et al, Acrogranin was detected in 95% of ovarian cancer specimens (11) . In a comparative analysis of pooled library transcripts between ovarian border-line tumor and invasive carcinoma, whereas Jones et al (12) reported that Acrogranin was expressed only in the latter. In our limited study on human specimens of ovarian cancer and borderline tumors, Acrogranin protein is more strongly expressed in cancer specimens. These data suggest that Acrogranin serves as an autocrine growth factor for epithelial ovarian cancer, and it is plausible that Acrogranin is also related to ovarian cancer development.
Therefore, we attempted to obtain more direct evidence that Acrogranin contributes to the development of ovarian cancer. Acrogranin was transfected into immortalized OSE cells (IOSE) that were previously established by introduction of hTERT and SV40 LT to cultured OSE. Overexpression of Acrogranin in IOSE by retrovirus-mediated transfection resulted in significant promotion of cell growth and enhanced colony formation in soft agar compared with empty vectortransfected IOSE cells. It has been reported that induction of Acrogranin in SW-13 human adrenal carcinoma cells resulted in increased cell proliferation and enhanced clonogenicity. On the other hand, transfection of ovarian cancer cells with antisense Acrogranin reduced cell growth and Sphase fraction, and resulted in loss of density-independent growth (12) . Our data indicate that Acrogranin overexpression has a similar cell-activating effect on phenotypically normal human cells as well as on cancer cells.
In terms of tumorigenicity in vivo, transfection of Acrogranin into hTERT and SV40 LT-immortalized OSE cells resulted in tumor formation in athymic nude mice. Although it was reported that overexpression of Acrogranin in a cancer cell line (SW-13) augmented the tumorigenicity in nude mice (17) , this is the first study showing that Acrogranin endows tumorigenicity to phenotypically normal constitutive RAS signaling by transfection of the oncogenic allele of RAS (18) (19) (20) (21) . In general, signals from growth factors are transmitted through tyrosine kinase-type receptors to RAS (22) . In this view, it is expected that growth factor signals may substitute for oncogenic RAS transfection. As we previously reported, ovarian surface epithelial cells immortalized by co-expression of hTERT and SV40 are transformed by c-ERBB2 instead of oncogenic RAS (13) . However, it has to be clarified if overexpression of growth factor itself can substitute for oncogenic RAS signal. Acrogranin activates the MAP kinase and phosphatidyl inositol-3 kinase (PI3K) signaling cascades (23) . Activated PI3K can substitute, at least in part, for oncogenic RAS signal in de novo transformation (24) . Hence, it is one of the possible mechanisms that Acrogranin exert oncogenicity via PI3K activation by substituting RAS signaling. However, we do not have direct evidence for this, and other possibilities cannot be excluded. In summary, our data show that the combination of hTERT, SV40 LT, and Acrogranin gene transfection into human ovarian surface epithelium induced tumorigenicity. This is evidence that a growth factor plays a direct role in malignant transformation in human cells. It also suggests that Acrogranin has a potent oncogenic property in ovarian carcinogenesis, and is thus possibly an important molecular target in therapy for this disease.
